Jointown released its 2026 interim report. Operating revenue was 87.28 billion yuan, up 7.6% year on year. Net profit attributable to the parent was 1.2 billion yuan, down 16.9% year on year. Net profit attributable to the parent after deducting non-recurring items was 982 million yuan, up 3.2% year on year. Net operating cash flow was negative 2.781 billion yuan, an improvement of 1.4% year on year. In the second quarter, operating revenue was 42.5 billion yuan, up 8.7% year on year. Net profit attributable to the parent was 467 million yuan, down 1.7% year on year. Net profit attributable to the parent after deducting non-recurring items was 439 million yuan, down 1.2% year on year. As of the end of the second quarter, total assets were 120.775 billion yuan, up 3.8% from the end of the previous year. Net assets attributable to the parent were 28.755 billion yuan, up 0.7% from the end of the previous year. During the reporting period, the company's B2C e-commerce and pharmaceutical manufacturing self-operated businesses achieved year-on-year growth of 19.10% and 24.47% respectively, and it has established a nationwide intelligent logistics network, forming an efficient supply chain model integrating business-to-business and business-to-consumer operations.
Jointown Pharmaceutical Group Co LtdNet profit attributable to parent fell 16.9% year on year, despite revenue growth.
